A Study of Irinotecan Liposome in Advanced Pancreatic Cancer
Status:
Enrolling by invitation
Trial end date:
2023-09-25
Target enrollment:
Participant gender:
Summary
To determine the safety and tolerability of irinotecan liposome in combination with
oxaliplatin and 5-FU/LV in subjects with advanced pancreatic cancer who have not received
prior systemic chemotherapy